Investsud

TrustUp is a platform designed to connect homeowners with verified home improvement contractors. It operates a marketplace that facilitates the search for and hiring of reliable professionals for various construction and renovation services. By ensuring a guarantee of quality work, TrustUp enables customers to access consistent and effective professional services for their home projects. The platform aims to streamline the process of finding suitable contractors, ultimately enhancing the home improvement experience for homeowners.

Brenus Pharma is a biotechnology company focused on developing innovative allogeneic cell-based immunotherapies aimed at treating solid tumors. The company specializes in creating anti-cancer cell vaccines that leverage the patient’s immune system to prevent cancer resistance during treatment. With a strong emphasis on derisking strategies, Brenus Pharma generates multiple candidates efficiently, allowing for cost-effective scaling and a strategic entry into the market alongside established standards of care. The company boasts a robust intellectual property portfolio and a highly skilled team, including renowned oncologists, who work to educate the immune system to recognize tumor-associated and tumor-specific antigens. This approach enhances the potential for effective responses in cancer treatment.

Myocene, headquartered in Liège, Belgium, specializes in developing innovative sports technology devices. Their primary product measures muscle fatigue and performance using proprietary algorithms and artificial intelligence, empowering athletes to track their progress accurately and conveniently.

AbolerIS Pharma is a biotechnology company based in Nantes, France, specializing in the development of immune-modulators aimed at treating transplant rejection, graft-versus-host disease, and autoimmune diseases. Incorporated in 2019, the company offers innovative products such as Anti-CD45RC, a monoclonal antibody designed to deplete effector T cells, and IL-34, a cytokine that promotes the induction of tolerogenic macrophages and regulatory T cells. AbolerIS Pharma employs a unique therapeutic approach that fosters immune tolerance while preserving beneficial immune responses in the context of inflammatory, autoimmune, and degenerative diseases. This strategy allows the company to focus on advancing novel drugs to address significant unmet medical needs in these therapeutic areas.

Cikisi is a company that specializes in Web Intelligence, focusing on the collection, searching, and filtering of web information to help organizations leverage relevant data for their growth. It develops and commercializes the Cikisi WMT, a Web Intelligence Solution designed to provide real-time, tailored market insights. By utilizing artificial intelligence, Cikisi's software simplifies and optimizes the processes of gathering, processing, and disseminating pertinent information, thereby enabling companies to accelerate their decision-making. Through its innovative solutions, Cikisi aims to enhance the effectiveness of businesses in navigating the complexities of the digital information landscape.

Curvo is an investment application designed to enhance the financial well-being of young Europeans through index investing. The platform allows users to quickly create an account and invest in a diversified portfolio of index funds tailored to their individual goals and personalities. By simplifying the complexities of investing, Curvo makes it accessible to anyone starting from a minimum investment of €50. The application provides a user-friendly and secure environment, empowering users to effectively manage their savings and prepare for their financial future.

DeuterOncology is a preclinical-stage biotechnology company dedicated to advancing cancer treatment through innovative therapies. The firm is developing a first-in-class dual MET and RAS pathway inhibitor, which is currently undergoing preclinical investigation. This lead compound aims to serve as a targeted therapy primarily for lung cancer, while also holding promise for broader applications in oncology when used in combination with standard of care and other targeted agents. By focusing on optimizing treatment outcomes, DeuterOncology seeks to empower medical professionals in their efforts to effectively combat cancer.

Eclo is an urban farming company that specializes in producing exotic mushrooms by utilizing waste materials, specifically spent beer grain. By recycling this byproduct, Eclo not only contributes to sustainable practices but also provides customers with organic mushrooms and baby herbs. The company's focus on innovative waste management in agriculture highlights its commitment to environmental responsibility while meeting the growing demand for high-quality, organic produce.